Baxter buys SuppreMol in €200m deal
SuppreMol is involved in development of treatment options for autoimmune and allergic diseases. Besides owning and operating SuppreMol’s Munich operations, Baxter will also own SuppreMol’s complete early-stage development
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.